CD8A and neoplasm: Thus, although effects on NK cells (Dong et al., 2019), MDSC (Harnoss et al., 2020), or CD8+ T cells (Kamimura and Bevan, 2008) may also contribute, the attenuation of CT26 tumor growth by IRE1α inhibition is attributable, at least in part, to an elevated tumor infiltration, MHC-I expression, and tumor-antigen cross-presentation by cDC1s, which augments the recruitment and activation of tumor-reactive CD8+ T cells.